With the first Phase I data and the first patents relating to deuterium-modified compounds firmly in hand, Concert Pharmaceuticals Inc. set out looking for a partner and ended up scoring big by signing GlaxoSmithKline plc to a multiproduct collaboration that could be worth more than $1 billion in up-front and milestone payments. (BioWorld Today)